User profiles for Gregory J. Dore
 | Gregory DoreUNSW Sydney Verified email at kirby.unsw.edu.au Cited by 44502 |
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
…, ML Abate, M Bassendine, U Spengler, GJ Dore… - Nature …, 2009 - nature.com
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists
of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify …
of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify …
[HTML][HTML] Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection
A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
…, JR Daruich, V De Ledinghen, GJ Dore… - The lancet …, 2017 - thelancet.com
Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …
Epidemiology and natural history of HCV infection
Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is
highest in Egypt at >10% of the general population and China has the most people with HCV (…
highest in Egypt at >10% of the general population and China has the most people with HCV (…
[PDF][PDF] Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression
Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV)
infection are heterogeneous. We aimed to estimate stage‐specific fibrosis …
infection are heterogeneous. We aimed to estimate stage‐specific fibrosis …
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study
Background Since the release of the first global hepatitis elimination targets in 2016, and until
the COVID-19 pandemic started in early 2020, many countries and territories were making …
the COVID-19 pandemic started in early 2020, many countries and territories were making …
Estimating progression to cirrhosis in chronic hepatitis C virus infection
To gain a clearer understanding of the rate of progression to cirrhosis and its determinants
in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic …
in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic …
[HTML][HTML] A multinational Delphi consensus to end the COVID-19 public health threat
Despite notable scientific and medical advances, broader political, socioeconomic and
behavioural factors continue to undercut the response to the COVID-19 pandemic 1, 2. Here we …
behavioural factors continue to undercut the response to the COVID-19 pandemic 1, 2. Here we …
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3 …
Background Although the addition of the HCV NS3/4A protease inhibitors boceprevir and
telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained …
telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained …
[PDF][PDF] Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals
Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …
(PWID) cannot be achieved by harm reduction interventions such as needle exchange and …